Evidence map›Paper›PMID 40235757›Full record

ArticleQuantitative imaging in medicine and surgery2025

Artificial intelligence electrocardiogram as a novel screening tool to detect and longitudinally monitor high-risk echocardiographic features in hypertrophic cardiomyopathy.

Hongxia Ning, Qi Yu, Fanxin Kong, Guangyuan Li, Yonghuai Wang, Bo Zhang, Yong Feng, Chunyan Ma

Abstract read
In one paragraph

Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hongxia Ning *Department of Cardiovascular Ultrasound, the First Hospital of China Medical University, Shenyang, China.
Qi Yu *Computer Science and Engineering, Northeastern University, Shenyang, China.
Fanxin KongDepartment of Cardiovascular Ultrasound, the First Hospital of China Medical University, Shenyang, China.
Guangyuan LiDepartment of Cardiovascular Ultrasound, the First Hospital of China Medical University, Shenyang, China.
Yonghuai WangDepartment of Cardiovascular Ultrasound, the First Hospital of China Medical University, Shenyang, China.
Bo ZhangDepartment of Ultrasound Diagnosis, Dalian Municipal Friendship Hospital, Dalian, China.
Yong FengComputer Science and Engineering, Northeastern University, Shenyang, China.
Chunyan MaDepartment of Cardiovascular Ultrasound, the First Hospital of China Medical University, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Current practice protocols for hypertrophic cardiomyopathy (HCM) recommend integrating crucial high-risk echocardiographic features associated with adverse prognosis into patient management. However, echocardiography is resource-limited and few powerful screening tools are available for risk assessment in the community. We aimed to devise an artificial intelligence (AI)-electrocardiogram (ECG) to identify high-risk echocardiographic features and monitor feature changes during long-term follow-up. Methods: Patients with HCM from two hospitals who underwent both ECG and echocardiography within a 14-day window were retrospectively identified. One site (n=2,591) was used for training, validation and testing, and the other site (n=171) was used for external validation. An AI-ECG model was trained to predict the presence of any of the following four high-risk echocardiographic features: resting left ventricular outflow tract obstruction (LVOTO), massive left ventricular hypertrophy (LVH), systolic dysfunction, and apical aneurysm. Results: The AI-ECG model exhibited an area under the receiver operating characteristic curve (AUROC) of 0.81 [95% confidence interval (CI): 0.76-0.86] and 0.80 (95% CI: 0.72-0.87) in the testing and external validation set for identifying high-risk features. During a median follow-up of 37 months (interquartile range, 30-53 months), in the testing set, 30 patients with no high-risk features at baseline were evaluated. Ten patients developed new high-risk features, and changes in the predicted probability score was well matched to the trend of changes in risk status. Patients with false-positive results at baseline had a threefold increased risk of developing high-risk features compared with the true-negatives [hazard ratio (HR) 3.36, 95% CI: 0.77-14.65; P=0.037]. Conclusions: The AI-ECG model effectively identified and longitudinally monitored high-risk echocardiographic features and may serve as a powerful community screening tool.

Indexed as

Artificial intelligence (AI)electrocardiogram (ECG)hypertrophic cardiomyopathy (HCM)risk stratification

Identifiers

PMID40235757
PMCPMC11994496

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.